CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 12

Some of the metrics are blocked by your
consent settings
Genetic and Mechanistic Diversity in Hemophagocytic Lymphohistiocytosis
(2018)
Ivan K. Chinn
;
Olive S. Eckstein
;
Erin C. Peckham-Gregory
;
Baruch R. Goldberg
;
Lisa R. Forbes
1
Some of the metrics are blocked by your
consent settings
Proteasome disorders and inborn errors of immunity
(2023)
M. Cecilia Poli
<jats:title>Summary</jats:title><jats:p>Inborn errors of immunity (IEI) or primary immune deficiencies (PIDD) are caused by variants in genes encoding for molecules that are relevant to the innate or adaptive immune response. To date, defects in more than 450 different genes have been identified as causes of IEI, causing a constellation of heterogeneous clinical manifestations ranging from increased susceptibility to infection, to autoimmunity or autoinflammation. IEI that are mainly characterized by autoinflammation are broadly classified according to the inflammatory pathway that they predominantly perturb. Among autoinflammatory IEI are those characterized by the transcriptional upregulation of type I interferon genes and are referred to as interferonopathies. Within the spectrum of interferonopathies, genetic defects that affect the proteasome have been described to cause autoinflammatory disease and represent a growing area of investigation. This review is focused on describing the clinical, genetic, and molecular aspects of IEI associated with mutations that affect the proteasome and how the study of these diseases has contributed to delineate therapeutic interventions.</jats:p>
2Scopus© Citations 5
Some of the metrics are blocked by your
consent settings
Disparities in Diagnosis, Access to Specialist Care, and Treatment for Inborn Errors of Immunity
(2023)
Monica G. Lawrence
;
Nicholas L. Rider
;
Charlotte Cunningham-Rundles
;
M. Cecilia Poli
1Scopus© Citations 10
Some of the metrics are blocked by your
consent settings
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency
(2023)
Tom Le Voyer
;
Audrey V. Parent
;
Xian Liu
;
Axel Cederholm
;
Adrian Gervais
<jats:title>Abstract</jats:title><jats:p>Patients with autoimmune polyendocrinopathy syndrome type 1 (APS-1) caused by autosomal recessive AIRE deficiency produce autoantibodies that neutralize type I interferons (IFNs)<jats:sup>1,2</jats:sup>, conferring a predisposition to life-threatening COVID-19 pneumonia<jats:sup>3</jats:sup>. Here we report that patients with autosomal recessive NIK or RELB deficiency, or a specific type of autosomal-dominant NF-κB2 deficiency, also have neutralizing autoantibodies against type I IFNs and are at higher risk of getting life-threatening COVID-19 pneumonia. In patients with autosomal-dominant NF-κB2 deficiency, these autoantibodies are found only in individuals who are heterozygous for variants associated with both transcription (p52 activity) loss of function (LOF) due to impaired p100 processing to generate p52, and regulatory (IκBδ activity) gain of function (GOF) due to the accumulation of unprocessed p100, therefore increasing the inhibitory activity of IκBδ (hereafter, p52<jats:sup>LOF</jats:sup>/IκBδ<jats:sup>GOF</jats:sup>). By contrast, neutralizing autoantibodies against type I IFNs are not found in individuals who are heterozygous for <jats:italic>NFKB2</jats:italic> variants causing haploinsufficiency of p100 and p52 (hereafter, p52<jats:sup>LOF</jats:sup>/IκBδ<jats:sup>LOF</jats:sup>) or gain-of-function of p52 (hereafter, p52<jats:sup>GOF</jats:sup>/IκBδ<jats:sup>LOF</jats:sup>). In contrast to patients with APS-1, patients with disorders of NIK, RELB or NF-κB2 have very few tissue-specific autoantibodies. However, their thymuses have an abnormal structure, with few AIRE-expressing medullary thymic epithelial cells. Human inborn errors of the alternative NF-κB pathway impair the development of AIRE-expressing medullary thymic epithelial cells, thereby underlying the production of autoantibodies against type I IFNs and predisposition to viral diseases.</jats:p>
3Scopus© Citations 90
Some of the metrics are blocked by your
consent settings
Immune Dysregulation Mimicking Systemic Lupus Erythematosus in a Patient With Lysinuric Protein Intolerance: Case Report and Review of the Literature
(2021)
Josefina Longeri Contreras
;
Mabel A. Ladino
;
Katherine Aránguiz
;
Gonzalo P. Mendez
;
Zeynep Coban-Akdemir
<jats:p>Lysinuric protein intolerance (LPI) is an inborn error of metabolism caused by defective transport of cationic amino acids in epithelial cells of intestines, kidneys and other tissues as well as non-epithelial cells including macrophages. LPI is caused by biallelic, pathogenic variants in <jats:italic>SLC7A7</jats:italic>. The clinical phenotype of LPI includes failure to thrive and multi-system disease including hematologic, neurologic, pulmonary and renal manifestations. Individual presentations are extremely variable, often leading to misdiagnosis or delayed diagnosis. Here we describe a patient that clinically presented with immune dysregulation in the setting of early-onset systemic lupus erythematosus (SLE), including renal involvement, in whom an LPI diagnosis was suspected post-mortem based on exome sequencing analysis. A review of the literature was performed to provide an overview of the clinical spectrum and immune mechanisms involved in this disease. The precise mechanism by which ineffective amino acid transport triggers systemic inflammatory features is not yet understood. However, LPI should be considered in the differential diagnosis of early-onset SLE, particularly in the absence of response to immunosuppressive therapy.</jats:p>
5Scopus© Citations 18
Some of the metrics are blocked by your
consent settings
HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related autoinflammatory disease
(2021)
Caridad Martinez
;
Frédéric Ebstein
;
Sarah K. Nicholas
;
Marietta De Guzman
;
Lisa R. Forbes
8Scopus© Citations 21
Some of the metrics are blocked by your
consent settings
Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
(2021)
Tiphanie P. Vogel
;
Karina A. Top
;
Christos Karatzios
;
David C. Hilmers
;
Lorena I. Tapia
8Scopus© Citations 185
Some of the metrics are blocked by your
consent settings
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study
(2021)
Isabelle Meyts
;
Giorgia Bucciol
;
Isabella Quinti
;
Bénédicte Neven
;
Alain Fischer
Scopus© Citations 309 3
Some of the metrics are blocked by your
consent settings
Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with neutropenia
(2022)
Matilde I. Conte
;
M. Cecilia Poli
;
Angelo Taglialatela
;
Giuseppe Leuzzi
;
Ivan K. Chinn
9Scopus© Citations 13
Some of the metrics are blocked by your
consent settings
Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders
(2022)
Lisa R. Forbes
;
Olive S. Eckstein
;
Nitya Gulati
;
Erin C. Peckham-Gregory
;
Nmazuo W. Ozuah
14Scopus© Citations 15

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results